Geode Capital Management LLC Boosts Stock Holdings in Glaukos Co. (NYSE:GKOS)

Geode Capital Management LLC grew its holdings in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 6.0% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,172,016 shares of the medical instruments supplier's stock after buying an additional 66,134 shares during the period. Geode Capital Management LLC owned approximately 2.13% of Glaukos worth $152,722,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the stock. Raymond James & Associates lifted its holdings in shares of Glaukos by 23.2% in the 2nd quarter. Raymond James & Associates now owns 13,017 shares of the medical instruments supplier's stock worth $1,541,000 after purchasing an additional 2,452 shares in the last quarter. Fifth Third Wealth Advisors LLC bought a new position in shares of Glaukos during the 2nd quarter worth approximately $187,000. Louisiana State Employees Retirement System boosted its stake in shares of Glaukos by 4.5% in the 2nd quarter. Louisiana State Employees Retirement System now owns 25,300 shares of the medical instruments supplier's stock worth $2,994,000 after buying an additional 1,100 shares during the last quarter. EFG Asset Management North America Corp. grew its stake in Glaukos by 0.5% in the 2nd quarter. EFG Asset Management North America Corp. now owns 27,205 shares of the medical instruments supplier's stock valued at $3,216,000 after purchasing an additional 128 shares during the period. Finally, Bank of New York Mellon Corp increased its holdings in Glaukos by 6.8% during the second quarter. Bank of New York Mellon Corp now owns 413,680 shares of the medical instruments supplier's stock worth $48,959,000 after buying an additional 26,510 shares during the last quarter. Institutional investors and hedge funds own 99.04% of the company's stock.

Insiders Place Their Bets

In other news, COO Joseph E. Gilliam sold 2,275 shares of the business's stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total transaction of $316,156.75. Following the sale, the chief operating officer now owns 102,169 shares in the company, valued at approximately $14,198,425.93. The trade was a 2.18 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Gilbert H. Kliman sold 2,000 shares of the business's stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $144.01, for a total transaction of $288,020.00. Following the sale, the director now directly owns 32,336 shares in the company, valued at $4,656,707.36. The trade was a 5.82 % decrease in their position. The disclosure for this sale can be found here. Insiders own 6.40% of the company's stock.

Glaukos Trading Up 1.5 %

Shares of Glaukos stock traded up $2.23 during trading on Tuesday, reaching $146.36. The company's stock had a trading volume of 703,556 shares, compared to its average volume of 570,555. The company has a market cap of $8.07 billion, a price-to-earnings ratio of -48.46 and a beta of 1.03. The firm's 50-day moving average is $136.61 and its two-hundred day moving average is $127.28. Glaukos Co. has a 52-week low of $74.75 and a 52-week high of $147.65. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.20. The business had revenue of $96.70 million for the quarter, compared to analysts' expectations of $91.50 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The business's quarterly revenue was up 23.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.50) EPS. On average, sell-side analysts anticipate that Glaukos Co. will post -1.89 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on GKOS. Stifel Nicolaus boosted their target price on Glaukos from $145.00 to $153.00 and gave the company a "buy" rating in a research note on Monday, December 2nd. StockNews.com raised shares of Glaukos from a "sell" rating to a "hold" rating in a report on Monday, October 21st. UBS Group assumed coverage on shares of Glaukos in a report on Friday, December 6th. They set a "buy" rating and a $182.00 target price on the stock. Citigroup upgraded Glaukos from a "neutral" rating to a "buy" rating and raised their target price for the stock from $132.00 to $162.00 in a research note on Wednesday, December 11th. Finally, Wells Fargo & Company boosted their price target on shares of Glaukos from $145.00 to $153.00 and gave the company an "overweight" rating in a research report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $143.17.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.